Related Experiment Video
Updated: Jul 1, 2025

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Angina pectoris 2023: With and without obstructive coronary artery disease: Epidemiology, diagnosis, prognosis, and
1Imperial College London, Imperial College Healthcare NHS Trust, Du Cane Rd, London W12 0HS, UK.
Angina causes significant illness globally. Improving diagnosis and treatment requires understanding diverse cardiac and vascular causes beyond epicardial disease.
Area of Science:
- Cardiology
- Vascular Medicine
Background:
- Angina represents a major global health burden, contributing to substantial morbidity.
- Current angina evaluation is inconsistent and complicated by numerous contributing factors.
- Diagnosis often overemphasizes epicardial disease, neglecting other potential cardiac, non-cardiac, macrovascular, and microvascular origins of chest pain.
Approach:
- Standardized diagnostic pathways are crucial for consistent angina assessment.
- Novel approaches to angina evaluation are needed to improve diagnostic accuracy.
- Personalized treatment strategies can be developed by better understanding angina etiology.
Key Points:
- Chest pain in angina has multifactorial origins, including cardiac, non-cardiac, macrovascular, and microvascular causes.
- The current diagnostic focus on epicardial disease is insufficient for comprehensive angina evaluation.
- Variability in angina assessment complicates accurate diagnosis and effective management.
Conclusions:
- Implementing standardized diagnostic pathways can enhance the understanding and management of angina.
- Novel assessment strategies hold promise for improving patient outcomes in angina.
- A personalized treatment approach, informed by a thorough understanding of angina causes, is essential for optimal patient care.
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

